Biomaterial Database

Severe hypoprothrombinemia following propylthiouracil treatment of thyrotoxicosis. 1951

C G CRADDOCK, and D SHOTTON, and C L CROCKETT, and B S LEAVELL

UI	MeSH Term	Description	Entries
D007020	Hypoprothrombinemias	Absence or reduced levels of PROTHROMBIN in the blood.	Factor II Deficiency,Prothrombin Deficiency,Deficiency, Factor II,Hypoprothrombinemia,Deficiencies, Factor II,Deficiencies, Prothrombin,Deficiency, Prothrombin,Factor II Deficiencies,Prothrombin Deficiencies
D011441	Propylthiouracil	A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)	6-Propyl-2-Thiouracil,6 Propyl 2 Thiouracil
D011516	Prothrombin	A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.	Coagulation Factor II,Factor II,Blood Coagulation Factor II,Differentiation Reversal Factor,Factor II, Coagulation,Factor, Differentiation Reversal,II, Coagulation Factor
D006490	Hemostatics	Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.	Antihemorrhagic,Hemostatic,Antihemorrhagics
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013889	Thiouracil	Occurs in seeds of Brassica and Crucifera species. Thiouracil has been used as antithyroid, coronary vasodilator, and in congestive heart failure although its use has been largely supplanted by other drugs. It is known to cause blood dyscrasias and suspected of terato- and carcinogenesis.
D013971	Thyrotoxicosis	A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.	Thyrotoxicoses